Mesh : Humans Neprilysin / pharmacology Ventricular Remodeling Tetrazoles / pharmacology Treatment Outcome Angiotensin Receptor Antagonists / therapeutic use Stroke Volume Heart Failure / drug therapy diagnosis Antihypertensive Agents

来  源:   DOI:

Abstract:
Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).
摘要:
不良心脏重塑是指由于心肌壁应力增加而导致心脏进行性结构和功能改变。存活心肌的丧失,和神经激素刺激.针对心力衰竭(HF)的指南指导的药物治疗包括血管紧张素受体-脑啡肽酶抑制剂(ARNI)(沙库巴曲/缬沙坦),β-受体阻滞剂,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,和盐皮质激素受体拮抗剂(MRA)。ARNI在印度的处方不足,尽管其具有吸引力的安全性和有效性。因此,共识讨论了心脏重塑管理中与ARNI相关的目标和主题,和专家分享了他们对早期及时干预ARNI有效剂量的观点,以改善诊断并提高心脏逆转重塑(CRR)的死亡率和发病率。
公众号